Oxford Gene Technology Ltd. Release: New Whitepaper Discusses How Best to Utilise Next Generation Techniques for Genomic Research

Oxford, UK – 2 August 2011. Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has released a new white paper discussing the relative merits of DNA microarrays and next generation sequencing (NGS) for human genome analysis. Although the development of genome analysis technologies such as DNA microarrays and NGS has provided the researcher with the unique ability to screen for sequence variants of clinical relevance, each technology has its own unique advantages, meaning that choosing the most appropriate technology for any given study can be challenging. Therefore, the resulting whitepaper, which can be downloaded here, discusses the essential factors to consider when selecting the optimal platform for a specific study. The white paper discusses issues such as the suitability of microarrays and sequencing for various applications, the relative costs associated with each technology and how to overcome the challenges posed by the analysis of large and complex datasets.

To download the free whitepaper, visit www.ogt.co.uk/OGTwhitepaper.

For further information, please contact:

Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF

T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk

W: www.ogt.co.uk

About Oxford Gene Technology

Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.

Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high-quality genomic data to customers worldwide. OGT’s CytoSure™ cytogenetics array, labelling and interpretation software products and services provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.

Biomarker Discovery: OGT delivers tailored biomarker discovery solutions that optimise drug and diagnostic development programmes. With expertise in genomic and proteomic diagnostic biomarkers, OGT provides highly specific customised biomarker panels for cancer and other diseases, both for direct sale and also for collaboration with partner companies.

CytoSure™: For research use only

This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.